Navigation Links
Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzyme's Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch
Date:11/25/2013

EXTON, Pa., Nov. 25, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that two-thirds of surveyed U.S. neurologists have prescribed Genzyme's Aubagio, the second oral disease-modifying therapy (DMT) to reach the multiple sclerosis (MS) market, to at least one of their MS patients at one year post-launch. This increase in prescriber base represents a modest expansion compared with six months ago when Biogen Idec's Tecfidera, the third oral DMT to market, became commercially available.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

Neurologist-reported patient share for Aubagio among relapsing-remitting MS (RR-MS) patients treated with DMTs has also remained stable at two percent over the past six months. Reflecting increased product awareness and neurologist familiarity compared with earlier in the launch, significantly more surveyed neurologists now know that Aubagio is dosed once daily, providing a potential point of differentiation with recently launched, twice-daily Tecfidera. In fact, while Aubagio's oral formulation continues to be identified top-of-mind as the product's single biggest advantage compared with other currently available treatment options for MS, more surveyed neurologists now mention Aubagio's once-daily administration as its biggest advantage than at one, three, and six months post-launch.  

The recently published LaunchTrends®: Aubagio Wave 4 report finds that, over the next six months, surveyed neurologists expect Aubagio's patient share among DMT-treated RR-MS patients to increase significantly to 6 percent. This patient share nearly matches that of Novartis's Gilenya (7 percent), the first-to-market
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
3. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
4. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
5. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
6. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
7. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
8. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
9. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
10. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
11. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica US ... leading online community to help oncologists and other clinicians ... regarding the use of targeted therapies and immunotherapies, discusses ... and treatment.  Every September, Blood ... to raise awareness about blood cancers—helping to increase survival ...
(Date:9/19/2014)...  Alere Inc. (NYSE: ALR ), a ... today in support of President Barack Obama,s ... global leader in rapid diagnostics for infectious disease, we ... address the serious threat of antibiotic resistance. We look ... initiatives to promote the development of rapid point-of-care tests ...
(Date:9/19/2014)... and ORLANDO, Fla. , Sept. ... Inspire therapy continues to grow, with the publication of ... on-line in Otolaryngology – Head and Neck ... a worsening of both objective and subjective measures of ... attribute Inspire therapy for the reduction in obstructive sleep ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
... SAN DIEGO, Sept. 15 Volcano Corporation (Nasdaq: ... $100 million aggregate principal amount of 2.875 percent convertible senior ... of 1933, as amended. Prior to June 1, 2015, the ... holders will receive up to the principal amount of the ...
... A new study conducted by Dobson | DaVanzo & ... durable medical equipment (DME) may limit Medicare beneficiaries, access ... the quality of products that Medicare consumers rely on. ... of millions of Americans who require oxygen equipment and ...
Cached Medicine Technology:Volcano Corporation Prices $100 Million 2.875 Percent Convertible Senior Notes Due 2015 2Volcano Corporation Prices $100 Million 2.875 Percent Convertible Senior Notes Due 2015 3Volcano Corporation Prices $100 Million 2.875 Percent Convertible Senior Notes Due 2015 4Volcano Corporation Prices $100 Million 2.875 Percent Convertible Senior Notes Due 2015 5Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 2Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 3Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 4
(Date:9/19/2014)... (PRWEB) September 19, 2014 "I have ... getting wrinkles due to stretching the skin around my ... Ala. "This inspired me to design a more convenient ... CONTACT LENS SYSTEM provides a quicker, easier, more sanitary ... need to perform this task manually, saves time and ...
(Date:9/19/2014)... 2014 -- Recent two-generation approaches to reducing poverty ... increasing attention from researchers, advocates, and foundations. By ... them to move to jobs that offer a ... and education for children, these programs aim to ... according to a new report from the National ...
(Date:9/19/2014)... (HealthDay News) -- When it comes to firearm deaths, ... States, while the District of Columbia has the highest, ... deaths from gun-related violence -- including murders, suicides and ... the study revealed. Hawaii,s rate was roughly three per ... the District of Columbia had the highest rate of ...
(Date:9/19/2014)... Medical College of Wisconsin (MCW) scientists has identified a new ... mice and in humans. The findings are published in the ... Leah Solberg Woods, Ph.D., associate professor of pediatrics at MCW ... Institute, led the study and is the corresponding author of ... gene called Tpcn2 in which a variant was associated with ...
(Date:9/19/2014)... Top10BestSEOHosting.com today compares many professional Windows web hosting ... are the best suppliers of 2014. Clients who ... VPS and cloud hosting) at affordable rates can ... HostMonster ( http://www.hostmonster.com/track/seohosts ) helps business companies and ... the cost. As a top rated hosting provider, ...
Breaking Medicine News(10 mins):Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2
... use trends , , TUESDAY, March 4 (HealthDay News) -- When ... to give up the habit if it isn,t considered cool, ... research shows. , The findings will give prevention researchers ... embrace of illegal drugs, said study author Michelle Little, a ...
... to Take Action Against This Leading ... Cause of Home-Related Deaths, WASHINGTON, ... poisoning is the second leading,cause of home injury death in the ... one percent of U.S. adults ranked poisoning at the,top of the ...
... Estate Developer,s Foundation to Lead the ... in Ending Global Hunger, Improving Nutrition, NEW YORK, ... pledged a $15 million challenge grant to transform The ... Sciences in Rehovot, Israel. The gift will be the ...
... received a five-year, $20.5 million grant from the Bill ... investigating the biological factors underlying immune system control of ... provides support to the International HIV Controllers Study, which ... and has the overall goal of discovering information that ...
... Award and Massachusetts again takes ... top e-Prescribing State Honors, ... the leader in hosted services for email encryption and,e-prescribing, today ... 2008, for building awareness of improving,patient safety at the local ...
... AUSTIN, TX and TORONTO, March 4 /PRNewswire/ - ... dosing of healthy subjects in,a Phase I study ... from its,novel class of fatty acid biosyntheis inhibitors. ... and pharmacokinetics of a single,escalating oral dose. Affinium ...
Cached Medicine News:Health News:Troubled Boys Will Abandon Pot When It's Deemed Uncool 2Health News:New Home Safety Council(R) Research Shows the Majority of Families Underestimate the Danger of Poisoning Exposure at Home 2Health News:New Home Safety Council(R) Research Shows the Majority of Families Underestimate the Danger of Poisoning Exposure at Home 3Health News:New Home Safety Council(R) Research Shows the Majority of Families Underestimate the Danger of Poisoning Exposure at Home 4Health News:Robert H. Smith 'Feeding the Future' with $15 Million Gift to Hebrew University of Jerusalem 2Health News:Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study 2Health News:Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study 3Health News:Zix Corporation Celebrates National Patient Safety Awareness Week with Continued Success in e-Prescribing 2Health News:Zix Corporation Celebrates National Patient Safety Awareness Week with Continued Success in e-Prescribing 3Health News:Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic 2
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
InterVascular HemaPatch product line offers the vascular surgeon a range of collagen coated patches in a range of larger sizes angioplasty, or profundaplasty procedures without suture hole bleeding. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: